• Upstream Bio’s third-quarter 2026 net loss widened 22% year over year to $41.19 million.
• Collaboration revenue fell 42% year over year to $395,000.
• Cash, cash equivalents and short-term investments totaled $207.4 million at September 30, 2026, expected to fund planned operations through 2027.
• Phase 3 verekitug trials in severe asthma and chronic rhinosinusitis with nasal polyps are planned for the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873995) on November 10, 2026, and is solely responsible for the information contained therein.